Prognostic and predictive markers in colorectal cancer

Sangeetha Reddy, Maxwell Vergo, Al B. Benson

Research output: Contribution to journalReview article

Abstract

Prognostic and predictive biomarkers have revolutionized medicine by allowing individualized treatment decisions. Most notably in oncology, where treatment can be associatedwith significant toxicities and often unpredictable outcomes, there is a need to isolate patients that are likely to benefit from an intervention. In colorectal cancer, there are many markers being investigated but only a few that have sufficient evidence to warrant use in clinical practice. This paper will review these prominent biomarkers in both adjuvant and metastatic colorectal cancer and summarize the data regarding their utility. Themarkers reviewed include microsatellite instability, 18qLOH, gene profile assays such as ColoPrint and Oncotype DX, Kras, Braf, thymidylate synthase, and circulating tumor cells.The paper will also discuss optimal clinical trial design, with a focus on different validation strategies for emerging biomarkers. By highlighting the pertinent literature, the hope is to facilitate a personalized approach to colorectal cancer care.

Original languageEnglish (US)
Pages (from-to)267-274
Number of pages8
JournalCurrent Colorectal Cancer Reports
Volume7
Issue number4
DOIs
StatePublished - Aug 16 2011
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Biomarkers
Circulating Neoplastic Cells
Thymidylate Synthase
Microsatellite Instability
Precision Medicine
Clinical Trials
Therapeutics
Genes

Keywords

  • 18qLOH
  • Biomarkers
  • Braf
  • Circulating tumor cells
  • Clinical trial design
  • Colon
  • Coloprint
  • Colorectal
  • Deficient mismatch repair
  • dMMR
  • Gene profiling
  • Kras
  • Microsatellite instability
  • MSI-H
  • Oncotype dx
  • Predictive
  • Prognostic
  • Thymidylate synthase

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Prognostic and predictive markers in colorectal cancer. / Reddy, Sangeetha; Vergo, Maxwell; Benson, Al B.

In: Current Colorectal Cancer Reports, Vol. 7, No. 4, 16.08.2011, p. 267-274.

Research output: Contribution to journalReview article

Reddy, Sangeetha ; Vergo, Maxwell ; Benson, Al B. / Prognostic and predictive markers in colorectal cancer. In: Current Colorectal Cancer Reports. 2011 ; Vol. 7, No. 4. pp. 267-274.
@article{4037d4073c9c43c885463abc86c7cb70,
title = "Prognostic and predictive markers in colorectal cancer",
abstract = "Prognostic and predictive biomarkers have revolutionized medicine by allowing individualized treatment decisions. Most notably in oncology, where treatment can be associatedwith significant toxicities and often unpredictable outcomes, there is a need to isolate patients that are likely to benefit from an intervention. In colorectal cancer, there are many markers being investigated but only a few that have sufficient evidence to warrant use in clinical practice. This paper will review these prominent biomarkers in both adjuvant and metastatic colorectal cancer and summarize the data regarding their utility. Themarkers reviewed include microsatellite instability, 18qLOH, gene profile assays such as ColoPrint and Oncotype DX, Kras, Braf, thymidylate synthase, and circulating tumor cells.The paper will also discuss optimal clinical trial design, with a focus on different validation strategies for emerging biomarkers. By highlighting the pertinent literature, the hope is to facilitate a personalized approach to colorectal cancer care.",
keywords = "18qLOH, Biomarkers, Braf, Circulating tumor cells, Clinical trial design, Colon, Coloprint, Colorectal, Deficient mismatch repair, dMMR, Gene profiling, Kras, Microsatellite instability, MSI-H, Oncotype dx, Predictive, Prognostic, Thymidylate synthase",
author = "Sangeetha Reddy and Maxwell Vergo and Benson, {Al B.}",
year = "2011",
month = "8",
day = "16",
doi = "10.1007/s11888-011-0104-3",
language = "English (US)",
volume = "7",
pages = "267--274",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - Prognostic and predictive markers in colorectal cancer

AU - Reddy, Sangeetha

AU - Vergo, Maxwell

AU - Benson, Al B.

PY - 2011/8/16

Y1 - 2011/8/16

N2 - Prognostic and predictive biomarkers have revolutionized medicine by allowing individualized treatment decisions. Most notably in oncology, where treatment can be associatedwith significant toxicities and often unpredictable outcomes, there is a need to isolate patients that are likely to benefit from an intervention. In colorectal cancer, there are many markers being investigated but only a few that have sufficient evidence to warrant use in clinical practice. This paper will review these prominent biomarkers in both adjuvant and metastatic colorectal cancer and summarize the data regarding their utility. Themarkers reviewed include microsatellite instability, 18qLOH, gene profile assays such as ColoPrint and Oncotype DX, Kras, Braf, thymidylate synthase, and circulating tumor cells.The paper will also discuss optimal clinical trial design, with a focus on different validation strategies for emerging biomarkers. By highlighting the pertinent literature, the hope is to facilitate a personalized approach to colorectal cancer care.

AB - Prognostic and predictive biomarkers have revolutionized medicine by allowing individualized treatment decisions. Most notably in oncology, where treatment can be associatedwith significant toxicities and often unpredictable outcomes, there is a need to isolate patients that are likely to benefit from an intervention. In colorectal cancer, there are many markers being investigated but only a few that have sufficient evidence to warrant use in clinical practice. This paper will review these prominent biomarkers in both adjuvant and metastatic colorectal cancer and summarize the data regarding their utility. Themarkers reviewed include microsatellite instability, 18qLOH, gene profile assays such as ColoPrint and Oncotype DX, Kras, Braf, thymidylate synthase, and circulating tumor cells.The paper will also discuss optimal clinical trial design, with a focus on different validation strategies for emerging biomarkers. By highlighting the pertinent literature, the hope is to facilitate a personalized approach to colorectal cancer care.

KW - 18qLOH

KW - Biomarkers

KW - Braf

KW - Circulating tumor cells

KW - Clinical trial design

KW - Colon

KW - Coloprint

KW - Colorectal

KW - Deficient mismatch repair

KW - dMMR

KW - Gene profiling

KW - Kras

KW - Microsatellite instability

KW - MSI-H

KW - Oncotype dx

KW - Predictive

KW - Prognostic

KW - Thymidylate synthase

UR - http://www.scopus.com/inward/record.url?scp=84856220814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856220814&partnerID=8YFLogxK

U2 - 10.1007/s11888-011-0104-3

DO - 10.1007/s11888-011-0104-3

M3 - Review article

AN - SCOPUS:84856220814

VL - 7

SP - 267

EP - 274

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 4

ER -